Cantor Fitzgerald analyst Bryan Brokmeier raised his price target for Waters Corporation (WAT) to $173 and recommends buying the stock following the company's "strong" Q2 results and raised guidance. The analyst keeps a Buy rating on the name. Regarding a read-through to Bruker (BRKR), Brokmeier notes that Waters' academic market was broadly weak during the quarter. He remains positive on the shares, but is hesitant to call Waters' quarter an incremental positive for Bruker. The analyst prefers shares of PerkinElmer (PKI), which he notes has a higher exposure to the biopharma end market.